Evidence map›Paper›PMID 29791798›Full record

ArticleBioconjugate chemistry2018

Non-Natural Linker Configuration in 2,6-Dipeptidyl-Anthraquinones Enhances the Inhibition of TAR RNA Binding/Annealing Activities by HIV-1 NC and Tat Proteins.

Alice Sosic, Irene Saccone, Caterina Carraro, Thomas Kenderdine, Elia Gamba, Giuseppe Caliendo, Angela Corvino, Paola Di Vaio, Ferdinando Fiorino, Elisa Magli and 7 more

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. MultipleACS medicinal chemistry letters · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Alice SosicDipartimento di Scienze del Farmaco , Università di Padova , via Marzolo 5 , 35131 Padova , Italy.
Irene SacconeDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Caterina CarraroDipartimento di Scienze del Farmaco , Università di Padova , via Marzolo 5 , 35131 Padova , Italy.
Thomas KenderdineThe RNA Institute and Department of Chemistry , State University of New York , 1400 Washington Avenue , Albany , New York 12222 , United States.
Elia GambaDipartimento di Scienze del Farmaco , Università di Padova , via Marzolo 5 , 35131 Padova , Italy.
Giuseppe CaliendoDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Angela CorvinoDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Paola Di VaioDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Ferdinando FiorinoDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Elisa MagliDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Elisa PerissuttiDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Vincenzo SantagadaDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Beatrice SeverinoDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.ORCID 0000-0002-3887-8869
Valentina SpadaDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Dan FabrisThe RNA Institute and Department of Chemistry , State University of New York , 1400 Washington Avenue , Albany , New York 12222 , United States.
Francesco FrecenteseDipartimento di Farmacia , Università degli Studi di Napoli "Federico II" , Via D. Montesano 49 , 80131 Napoli , Italy.
Barbara GattoDipartimento di Scienze del Farmaco , Università di Padova , via Marzolo 5 , 35131 Padova , Italy.ORCID 0000-0001-9465-6913
University of Naples Federico II · ITUniversity of Padua · ITAlbany State University · US

Funding

Structural determinants of HIV-1 5'-UTR riboswitch and NC actuation by MS3DR01GM064328 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI FABRIS, DANIELE · 2001 to 2013
$3.8M
Characterization of ncRNAs' post-transcriptional modifications by antisense affinity capture and MS analysisR01GM121844 · NIGMS · UNIVERSITY OF CONNECTICUT STORRS · PI FABRIS, DANIELE · 2017 to 2021
$1.6M
NIGMS NIH HHS R01 GM064328NIGMS NIH HHS R01 GM121844
6 · The paper itself

Abstract

The HIV-1 nucleocapsid (NC) protein represents an excellent molecular target for the development of anti-retrovirals by virtue of its well-characterized chaperone activities, which play pivotal roles in essential steps of the viral life cycle. Our ongoing search for candidates able to impair NC binding/annealing activities led to the identification of peptidyl-anthraquinones as a promising class of nucleic acid ligands. Seeking to elucidate the inhibition determinants and increase the potency of this class of compounds, we have now explored the effects of chirality in the linker connecting the planar nucleus to the basic side chains. We show here that the non-natural linker configuration imparted unexpected TAR RNA targeting properties to the 2,6-peptidyl-anthraquinones and significantly enhanced their potency. Even if the new compounds were able to interact directly with the NC protein, they manifested a consistently higher affinity for the TAR RNA substrate and their TAR-binding properties mirrored their ability to interfere with NC-TAR interactions. Based on these findings, we propose that the viral Tat protein, sharing the same RNA substrate but acting in distinct phases of the viral life cycle, constitutes an additional druggable target for this class of peptidyl-anthraquinones. The inhibition of Tat-TAR interaction for the test compounds correlated again with their TAR-binding properties, while simultaneously failing to demonstrate any direct Tat-binding capabilities. These considerations highlighted the importance of TAR RNA in the elucidation of their inhibition mechanism, rather than direct protein inhibition. We have therefore identified anti-TAR compounds with dual in vitro inhibitory activity on different viral proteins, demonstrating that it is possible to develop multitarget compounds capable of interfering with processes mediated by the interactions of this essential RNA domain of HIV-1 genome with NC and Tat proteins.

Indexed as

AnthraquinonesDipeptidesGene Products, tatHIV-1HIV Long Terminal RepeatLigandsNucleic AcidsNucleocapsid ProteinsProtein BindingRNA, ViralAnthraquinonesDipeptidesGene Products, tatLigandsNucleic AcidsNucleocapsid ProteinsRNA, Viral

Identifiers

PMID29791798
PMCPMC7175782
OpenAlexW2804930151

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.